Microparticle Formulations for Delivery to the Upper and Central Respiratory Tract and Methods of Manufacture
申请人:Ansun Biopharma, Inc.
公开号:US20140154308A1
公开(公告)日:2014-06-05
Microparticle formulations are produced by contacting an aqueous solution of a protein or other active agent with an organic solvent, a counterion and a scavenging agent, and chilling the solution. The microparticles are useful for preparing stable, uniform pharmaceuticals of predetermined defined dimensions.
US6013773A
申请人:——
公开号:US6013773A
公开(公告)日:2000-01-11
[EN] FLUOROCARBON-LINKED PEPTIDE FORMULATION<br/>[FR] FORMULATION DE PEPTIDE LIÉ À UN FLUOROCARBONE
申请人:IMMUNE TARGETING SYSTEMS ITS LTD
公开号:WO2012090002A1
公开(公告)日:2012-07-05
The invention provides an aqueous acidic formulation suitable for use as in the preparation of a pharmaceutically acceptable fluorocarbon-linked peptide formulation, which aqueous formulation comprises a first fluorocarbon-linked peptide, wherein: the peptide linked to the fluorocarbon is at least 20 amino acid residues long, comprises at least 50% hydrophobic amino acid residues and has an isoelectric point greater than or equal to 7; and the fluorocarbon-linked peptide is present in micelles.
Glycosides and amino acyl esters of carbohydrates as potent inhibitors of angiotensin converting enzyme
About 12 glycosides prepared through amyloglucosidase catalysis and 23 amino acylesters of carbohydrates prepared through lipase catalysis in organic solvents showed angiotensin converting enzyme (ACE) inhibition activity. Both amino acylesters of carbohydrates and glycosides exhibited IC50 values for ACE inhibition in the 0.5 mM to 15.7 mM range. Eugenyl-D-glucoside (IC50: 0.5+/-0.04 mM), L-isoleucyl-D-glucose